Categories

Archive for July, 2011

MENGINGOCOCCAL OUTBREAK FROM STATE TO STATE IN AUSTRALIA

Sunday, July 31st, 2011

West Australian teenager dies

in meningococcal outbreak

Aja Styles

July 31, 2011 – 8:26AM

A West Australian man who had been studying at a north Queensland university has died of meningococcal disease.

A fellow student and friend was also being treated in hospital and others were taking antibiotics.

James Cook University held a memorial service yesterday for the 18-year-old, who was found dead in his room at the Catholic College on Wednesday night.

Advertisement: Story continues below

Catholic College principal Tom Tarttelin said all residents and staff at the college were shocked by the loss.

“He will be greatly missed in our community and our hearts go out to his family,” he said.

“We are offering support to all those who are grieving at this sad time.”

An autopsy indicated the student died from meningococcal disease, a university spokesman said.

The second-year medical student’s family from Perth arrived in Townsville on Thursday to take their son’s body home.

Meanwhile Queensland Health has offered clearance antibiotics to his closest contacts as a precaution.

One was admitted to Townsville Hospital on Friday suffering symptoms of the disease, the spokesman said.

“His disease was picked up quickly and he is recovering well in hospital,” he said.

Queensland Health’s public health medical officer in Townsville, Dr Steven Donohue, said further precautions would be taken as a result of the second case.

Antibiotics would be offered to a wider circle of contacts and information given to the whole university community.

They were also being offered counselling, after last week’s death of the student who had only just returned from his home state for the beginning of the second semester.

– with AAP  Sourced & published by Henry Sapiecha


DEPRESSION & ELECTRICAL IMPLANT IN THE BRAIN COULD BE THE ANSWER

Wednesday, July 6th, 2011

DEPRESSION CURES VIA ELECTRICAL IMPLANTS IN BRAIN

The anterior cingulate and prefrontal cortex (red) and frontal gyrus (orange) areas of the brain, which eTNS is said to activate (Image: NeuroSigma)

The World Health Organization has projected that by 2020, major depression will be the second-most significant cause for disability in the world, after heart disease. Along with psychotherapy, the disorder is usually treated using antidepressant drugs. There is often a frustrating trial-and-error period involved in finding the right drug for the right person, however, while side effects can include obesity, sexual dysfunction, and fatigue … to name a few. Los Angeles-based company NeuroSigma is now looking into an alternative drug-free therapy, that could ultimately incorporate electrodes implanted under the patient’s skin.

In an eight-week clinical trial conducted last June, researchers at UCLA externally stimulated the cranial trigeminal nerve of patients who suffered from depression. This was accomplished by attaching two electrodes to the skin of each subject’s forehead, which were in turn attached to a mobile phone-sized stimulating device. The external Trigeminal Nerve Stimulation (eTNS) process reportedly resulted in a 70 percent reduction in symptom severity during the trial, and a subsequent 80 percent remission rate, with none of the side effects associated with antidepressants.

The technology is licensed exclusively to NeuroSigma.

Last month, findings were presented on four more subjects from those trials, including functional neuroimaging PET data. It was determined that even brief exposure to eTNS increased blood flow to regions of the brain associated with depression and mood regulation. “These findings of a potential mechanism of action support our original hypothesis that electrical stimulation of the trigeminal nerves, located in facial skin tissue, can provide a very safe and effective means to send signals to key structures deep in the brain, thus providing a high-bandwidth pathway to the brain without current penetrating directly through the skull” said UCLA‘s Dr. Ian Cook.

A twenty-subject, double-blind second phase of the trials began this February, and should wrap up late this year.

NeuroSigma is meanwhile continuing development of eTNS, while also working on a version of the system that would utilize implantable subcutaneous electrodes. Known as sTNS, patients who responded well to eTNS could choose to switch over to it. The technology could also possibly be used to treat epilepsy and post-traumatic stress disorder.

Sourced & published by Henry Sapiecha